Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Patent metadata

Field	Value
Publication number	US-11872274-B2
Application number	US-202117194224-A
Country	US
Kind code	B2
Filing date	Mar 6, 2021
Priority date	Jan 21, 2014
Publication date	Jan 16, 2024
Grant date	Jan 16, 2024

Abstract

The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

First claim

The invention claimed is:

1. An immunogenic composition comprising a Streptococcus pneumoniae serotype 15B capsular polysaccharide-carrier protein glycoconjugate,
wherein the serotype 15B capsular polysaccharide-carrier protein glycoconjugate comprises at least 0.1 mM acetate per mM serotype 15B capsular polysaccharide,
wherein the immunogenic composition further comprises capsular polysaccharide-carrier protein glycoconjugates comprising S. pneumoniae serotypes 8, 10A, 11A, 12F, 22F and 33F and at least one additional capsular polysaccharide-carrier protein glycoconjugate from S. pneumoniae serotypes 2, 9N, 15C, 17F, and 20,
and wherein the carrier protein is selected from CRM 197 and tetanus toxoid (TT).

2. The immunogenic composition of claim 1 , wherein the serotype 15B capsular polysaccharide-carrier protein glycoconjugate comprises less than 50% of free serotype 15B capsular polysaccharide compared to the total amount of serotype 15B capsular polysaccharide.

3. The immunogenic composition of claim 1 , wherein the serotype 15B capsular polysaccharide-carrier protein glycoconjugate has a molecular weight of between 1000 kDa and 10,000 kDa.

4. The immunogenic composition of claim 1 , wherein the degree of conjugation of the serotype 15B capsular polysaccharide-carrier protein glycoconjugate is between 2 and 15.

5. The immunogenic composition of claim 1 , wherein the ratio (w/w) of serotype 15B capsular polysaccharide to the carrier protein in the serotype 15B capsular polysaccharide-carrier protein glycoconjugate is between 0.5 and 3.

6. The immunogenic composition of claim 1 , wherein the immunogenic composition further comprises at least one capsular polysaccharide-carrier protein glycoconjugate comprising a S. pneumoniae serotype selected from serotype 1, 2, 3, 4, 5, 6A, 6B, 7F, 9N, 9V, 14, 17F, 18C, 19A, 19F, 20 and 23F.

7. The immunogenic composition of claim 1 , wherein the immunogenic composition further comprises capsular polysaccharide-carrier protein glycoconjugates comprising S. pneumoniae serotypes 3, 7F, 9N, 17F and 19A.

8. The immunogenic composition of claim 1 , wherein the immunogenic composition further comprises capsular polysaccharide-carrier protein glycoconjugates comprising S. pneumoniae serotypes 3, 6A, 7F, 9N, 17F and 19A.

9. The immunogenic composition of claim 1 , wherein the immunogenic composition further comprises capsular polysaccharide-carrier protein glycoconjugates comprising S. pneumoniae serotypes 3, 7F, 9N, 17F, 19A and 23F.

10. The immunogenic composition of claim 1 , wherein the immunogenic composition further comprises capsular polysaccharide-carrier protein glycoconjugates comprising S. pneumoniae serotypes 3, 6A, 7F, 9N, 17F, 19A and 20.

11. The immunogenic composition of claim 1 , wherein the immunogenic composition further comprises capsular polysaccharide-carrier protein glycoconjugates comprising S. pneumoniae serotypes 1, 2, 3, 4, 5, 6B, 7F, 9N, 9V, 14, 17F, 18C, 19A, 19F, 20 and 23F.

12. The immunogenic composition of claim 1 , wherein the immunogenic composition further comprises capsular polysaccharide-carrier protein glycoconjugates comprising S. pneumoniae serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 9N, 9V, 14, 17F, 18C, 19A, 19F, 20 and 23F.

13. The immunogenic composition of claim 1 , further comprising at least one adjuvant.

14. The immunogenic composition of claim 13 , wherein the adjuvant is an aluminum adjuvant selected from aluminum phosphate, aluminum sulfate and aluminum hydroxide.

15. The immunogenic composition of claim 1 , further comprising a pharmaceutically acceptable excipient, carrier or diluent.

16. The immunogenic composition of claim 1 , wherein the immunogenic composition further comprises capsular polysaccharide-carrier protein glycoconjugates comprising S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9N, 9V, 14, 18C, 19A, 19F, and 23F.

Assignees

• Pfizer

Inventors

• Emini Emilio Anthony
• Watson Wendy Jo
• Prasad Avvari Krishna
• Han Mingming
• Kim Jin-Hwan
• Gu Jianxin
• Yang Yu-Ying
• Kainthan Rajesh Kumar
• Cooper David
• Pride Michael William
• Jansen Kathrin Ute

Classifications

• A61K39/092 Primary

  Streptococcus · CPC title

• A61K47/646

  the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines · CPC title

• A61K2039/55505

  Inorganic adjuvants · CPC title

• A61K2039/6037

  Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT] · CPC title

• A61K2039/70

  Multivalent vaccine · CPC title